Ascendis Pharma A/S (NASDAQ:ASND) Posts Earnings Results, Beats Estimates By $0.64 EPS

Ascendis Pharma A/S (NASDAQ:ASND) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64, Zacks reports.

Ascendis Pharma A/S Stock Performance

ASND stock traded up $6.63 on Wednesday, hitting $126.14. 762,557 shares of the company’s stock were exchanged, compared to its average volume of 452,948. The firm has a 50 day moving average price of $132.08 and a two-hundred day moving average price of $132.26. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $161.00. The stock has a market cap of $7.66 billion, a P/E ratio of -15.61 and a beta of 0.64.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ASND shares. JPMorgan Chase & Co. raised their target price on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Oppenheimer reduced their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday. Wedbush reissued an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Finally, StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $191.57.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.